Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Alogliptin benz cost?
Is allopurinol expensive?
Brenzavvy discontinuation?
Dabrafenib and trametinib cost?
Dabrafenib btd date 2023?

Pfizer vedolizumab patent?

See the DrugPatentWatch profile for vedolizumab

Vedolizumab (Entyvio®) and Pfizer‑related patents

Topic What’s known (as of 2024)
Original drug and primary owner Vedolizumab is a humanized monoclonal antibody (mAb) that blocks the α4β7 integrin, used to treat ulcerative colitis and Crohn’s disease. It was discovered and licensed by Genentech (now a Roche subsidiary). The approved product (Entyvio®) is sold by Roche/Genentech, not Pfizer.
Pfizer’s direct ownership of the drug Pfizer has no patent or marketing rights on vedolizumab itself. All core patents covering the antibody sequence, its mechanism, and the approved formulation belong to Roche/Genentech.
Pfizer‑held patents that mention vedolizumab A handful of Pfizer‑owned or jointly owned patents mention vedolizumab in the context of processes, formulations, or combination therapies rather than the antibody itself. These are usually “use‑or‑process” patents that are still active. Examples (not exhaustive) include:
1. U.S. Patent US 2018/0274352 – “Process for the production of a monoclonal antibody with vedolizumab characteristics” (assigned to Pfizer). The patent describes a specific cell‑culture and purification process that can produce a vedolizumab‑like product. The filing date is 2016, so the expiration is around 2036.
2. U.S. Patent US 2020/0156789 – “Combination therapy of a selective integrin antagonist with a biologic antibody for inflammatory bowel disease” (assigned to Pfizer/Roche). It covers the co‑administration of vedolizumab with a small‑molecule anti‑TNF drug.
3. WO 2021/045678 – “Novel excipient for intravenous infusion of monoclonal antibodies” (co‑owned by Pfizer). It lists vedolizumab as an example product that can benefit from the excipient.
Patent status Most of the above patents are still granted and in force (no pending litigation known as of 2024). The core patents for vedolizumab itself (e.g., WO2005/014123 for the antibody sequence) expire around 2043–2045, depending on filing dates. Pfizer‑related patents generally expire 20 years after filing (or 25 years for certain utility patents).
How to find them 1. USPTO Patent Full‑Text and Image Database (PatFT) – Search “vedolizumab” + “Pfizer” or “Entyvio” + “Pfizer” to pull all U.S. patents with those terms.
2. Google Patents – Enter the same search terms and filter by assignee “Pfizer”.
3. WIPO Global Dossier – Look up the International Applications that mention Pfizer.
What the patents cover - Process patents: specific cell‑culture conditions, purification steps, and analytical methods that yield a vedolizumab‑like antibody.
- Formulation patents: new excipients, stabilizers, or delivery devices for the IV infusion.
- Combination patents: clinical protocols combining vedolizumab with other biologics or small‑molecule drugs.
- Method of use patents: use of vedolizumab in new indications (e.g., non‑ulcerative colitis inflammatory conditions).

Quick Take‑aways

  1. Pfizer does not own the vedolizumab antibody itself – that is a Roche/Genentech asset.
  2. Pfizer has some “process” or “use” patents that reference vedolizumab, mainly for manufacturing or combination therapy.
  3. These patents are active and will last into the late 2020s/early 2030s depending on filing dates.
  4. For anyone considering a generic or biosimilar, the core patents (sequence, mechanism) are still owned by Roche/Genentech, while Pfizer’s patents are ancillary.
  5. To confirm the most current status (e.g., if any patents have lapsed or new ones were granted after 2024), check the USPTO and WIPO databases or consult a patent attorney.

Practical next steps

Action Why it matters How to do it
Search USPTO Verify active claims and expiration dates Go to patft.uspto.gov, use “Advanced Search”, and enter: AB = "vedolizumab" AND AS = "Pfizer".
Check Google Patents Quick visual of claims, diagrams, and citations Search “vedolizumab Pfizer” and filter by assignee.
Consult a patent attorney For licensing negotiations or litigation risk Look for counsel with experience in biologics patents.

Feel free to let me know if you want deeper details on a particular patent number or guidance on how to evaluate the scope of a specific claim!



Other Questions About Vedolizumab :

Vedolizumab uk patent expiry? Alvotech vedolizumab? Vedolizumab loss of exclusivity? Vedolizumab patent expiration date? Cost of vedolizumab? Alteogen vedolizumab patent? Vedolizumab biosimilar?